Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 16, Issue SUPPL. 1, 2006, Pages 241-246

  Karavasilis, V ^a   Malamou Mitsi, V ^a   Briasoulis, E ^a   Tsanou, E ^a   Kitsou, E ^b   Pavlidis, N ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b Medical Health Center of Paramythia   (Greece)

Author keywords

Angiogenesis; CD34; Microvessel density; Ovarian carcinoma; Thrombospondin 1; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; PLATINUM DERIVATIVE; THROMBOSPONDIN 1; TUMOR MARKER; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; GYNECOLOGIC SURGERY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROVASCULATURE; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE DISTRIBUTION; TUMOR BIOPSY; TUMOR VASCULARIZATION;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; MICROCIRCULATION; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33645348277     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00316.x     Document Type: Article

References (33)

1. Bray F Loos AH Tognazzo S La VC. Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. Int J Cancer 2004 113 977 90.
2. Goodman MT Correa CN Tung KH et al. Stage at diagnosis of ovarian cancer in the United States, 1992-1997. Cancer 2003 97 Suppl. 10 2648 59.
3. Gatta G Lasota MB Verdecchia A. Survival of European women with gynaecological tumours, during the period 1978-1989. EUROCARE Working Group. Eur J Cancer 1998 34 14 Spec No 2218 25.
4. See HT Kavanagh JJ Hu W Bast RC. Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer 2003 13 701 34.
5. Posadas EM Davidson B Kohn EC. Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Curr Opin Oncol 2004 16 478 84.
6. Abulafia O Triest WE Sherer DM. Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am J Obstet Gynecol 1997 177 541 7.
7. Alvarez AA Krigman HR Whitaker RS Dodge RK Rodriguez GC. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 1999 5 587 91.
8. Brustmann H Naude S. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynecol Oncol 2002 84 47 52.
9. Mattern J Stammler G Koomagi R Wallwiener D Kaufmann M Volm M. Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma. Anticancer Res 1997 17 621 4.
10. Heimburg S Oehler MK Papadopoulos T Caffier H Kristen P Dietl J. Prognostic relevance of the endothelial marker CD 34 in ovarian cancer. Anticancer Res 1999 19 2527 9.
11. Shen GH Ghazizadeh M Kawanami O et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 2000 83 196 203.
12. Vartanian RK Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Pathol 1994 144 1188 94.
13. Offersen BV Borre M Overgaard J. Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density. Eur J Cancer 2003 39 881 90.
14. Leung DW Cachianes G Kuang WJ Goeddel DV Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989 246 1306 9.
15. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002 2 795 803.
16. Iruela-Arispe ML Luque A Lee N. Thrombospondin modules and angiogenesis. Int J Biochem Cell Biol 2004 36 1070 8.
17. Nguyen HN Averette HE Hoskins W Sevin BU Penalver M Steren A. National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer 1993 72 3007 11.
18. Heimburg S Oehler MK Kristen P Papadopoulos T Caffier H. The endothelial marker CD 34 in the assessment of tumour vascularisation in ovarian cancer. Anticancer Res 1997 17 3149 51.
19. Schlingemann RO Rietveld FJ de Waal RM et al. Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest 1990 62 690 6.
20. Stone PJ Goodheart MJ Rose SL Smith BJ DeYoung BR Buller RE. The influence of microvessel density on ovarian carcinogenesis. Gynecol Oncol 2003 90 566 71.
21. Goodheart MJ Vasef MA Sood AK Davis CS Buller RE. Ovarian cancer p53 mutation is associated with tumor microvessel density. Gynecol Oncol 2002 86 85 90.
22. Hollingsworth HC Kohn EC Steinberg SM Rothenberg ML Merino MJ. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 1995 147 33 41.
23. Sonmezer M Gungor M Ensari A Ortac F. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor. Int J Gynecol Cancer 2004 14 82 8.
24. Hartenbach EM Olson TA Goswitz JJ et al. Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett 1997 121 169 75.
25. Fujimoto J Sakaguchi H Aoki I Khatun S Tamaya T. Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. Br J Cancer 2001 85 313 6.
26. Gadducci A Ferdeghini M Fanucchi A et al. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res 1999 19 1401 5.
27. Yamamoto S Konishi I Mandai M et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997 76 1221 7.
28. Alvarez AA Axelrod JR Whitaker RS et al. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients. Gynecol Oncol 2001 82 273 8.
29. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002 6 1 12.
30. Straume O Akslen LA. Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma. Angiogenesis 2003 6 295 301.
31. Kodama J Hashimoto I Seki N et al. Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor. Anticancer Res 2001 21 2983 7.
32. DiSaia PJ Bloss JD. Treatment of ovarian cancer: new strategies. Gynecol Oncol 2003 90 2 Pt 2 S24 32.
33. Byrne AT Ross L Holash J et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003 9 5721 8.